DrugPatentWatch Database Preview
Email this page to a colleague» See Plans and Pricing
« Back to Dashboard
SGI-1776 is an investigational drug.
There have been 27 clinical trials for SGI-1776. The most recent clinical trial was a Phase 2 trial, which was initiated on February 1st 2017.
The most common disease conditions in clinical trials are Leukemia, Myeloid, Acute, Leukemia, and Leukemia, Myeloid. The leading clinical trial sponsors are Astex Pharmaceuticals, National Cancer Institute (NCI), and M.D. Anderson Cancer Center.
There are two US patents protecting this investigational drug and sixteen international patents.
Recent Clinical Trials for SGI-1776
|Testing the Combination of Belinostat and SGI-110 (Guadecitabine) for the Treatment of Unresectable and Metastatic Conventional Chondrosarcoma||National Cancer Institute (NCI)||Phase 2|
|Guadecitabine and Nivolumab in Treating Refractory Metastatic Colorectal Cancer||Astex Pharmaceuticals||Phase 1/Phase 2|
|Guadecitabine and Nivolumab in Treating Refractory Metastatic Colorectal Cancer||Bristol-Myers Squibb||Phase 1/Phase 2|
Top disease conditions for SGI-1776
Top clinical trial sponsors for SGI-1776
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|SGI-1776||Start Trial||Imidazo[1,2-beta]pyridazine and pyrazolo[1,5-alpha]pyrimidine derivatives and their use as protein kinase inhibitors||SuperGen, Inc. (Dublin, CA)||Start Trial|
|SGI-1776||Start Trial||Imidazo[1,2-B]pyridazine and pyrazolo[1 .5-A]pyrimidine derivatives and their use as protein kinase inhibitors||Tolero Pharmaceuticals, Inc. (Salt Lake City, UT)||Start Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|SGI-1776||European Patent Office||2086979||2026-11-06||Start Trial|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|